


NH125

## Chemical Properties

CAS No. : 278603-08-0  
 Formula: C<sub>27</sub>H<sub>45</sub>IN<sub>2</sub>  
 Molecular Weight: 524.56  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	NH125 is a selective eEF-2 kinase inhibitor with IC <sub>50</sub> of 60 nM, >125-fold selectivity over PKC, PKA, and CaMKII, and also a potent histidine kinase inhibitor.
Targets(IC <sub>50</sub> )	CaMK,Antibacterial,Autophagy,Antifungal,PKA,PKC,Virus Protease
In vitro	In C6 glioma cells, NH125 decreases the cellular content of phospho-eEF-2 without affecting total content eEF-2 content, and blocks cell cycle transit at the G1-S boundary. NH125 potently inhibits cell viability of 10 cancer cells with IC <sub>50</sub> ranging from 0.7 to 4.8 μM. [1] NH125 effectively inhibits histidine protein kinases, including Envz, PhoQ, BvgS, EvgS, and thus produces potent anti-bacteria activities on oxacillin-resistant Staphylococcus aureus (ORSA), vancomycin-resistant Enterococcus faecalis (VRE), penicillin-resistant Streptococcus pneumoniae (PRS), and other Gram-positive and Gram-negative bacteria. [2] EEF2K inhibition by NH125 renders tumor cells more sensitive to curcumin and velcade, which possess ER stress-inducing action. [3]
In vivo	NH125 reduces blood pressure in SHR and ROS production, induction of inflammatory molecules, and hypertrophy in SHR superior mesenteric artery. [4]
Kinase Assay	eEF-2 Kinase Assay: eEF-2 kinase activity is measured by two methods: (a) a filter-based assay; and (b) by immunoblotting using antiphospho-eEF2 antibody. For both of these, reactions are carried out in 20 μl of total volume containing 50 mM HEPES (pH 7.5), 10 mM MgCl <sub>2</sub> , 1.5 mM CaCl <sub>2</sub> , 100 μg/ml calmodulin, 2 μM His-tagged eEF-2 and 400 nM GST-eEF-2 kinase, and ATP mixture [50 μM ATP with 1 μCi (γ- <sup>33</sup> P)ATP]. The kinase mixture without ATP is prepared on ice and then preincubated for 15 min at room temperature. Kinase reactions are started by adding ATP and allowed to progress at 30°C for 30 min. For the filter-based assay, the reaction is terminated by adding 20 μl of cold 1.5% phosphoric acid, and 5 μl of the reaction are applied to P81 Whatman phosphocellulose paper. The paper is washed three times in 500 ml of 0.5% phosphoric acid and once with 200 ml of acetone. The paper is then air-dried and immersed in 10 ml of scintillation mixture. Radioactivity is counted using a Beckton-Dickinson liquid scintillation counter. For immunoblotting, the reactions are stopped by addition of 20 μl of 3× Lamelli buffer [190 mM Tris (pH 6.8), 6% SDS, 30% glycerol, 15% 2-mercaptoethanol, and 0.003% bromphenol blue dye]. Samples are boiled for 5 min and resolved by 7% SDS-PAGE and processed for Western blotting as described below. Conditions for both assays are chosen to ensure linearity of the reaction with respect to time of incubation and concentration of enzyme.

## A DRUG SCREENING EXPERT

Cell Research	The viability of cells is measured using an MTT assay. Briefly, $5 \times 10^4$ cells are plated in 96-well plates and exposed to various concentrations of drug for 48–72 h. The formazan product formed after 4 h incubation with MTT is dissolved in 100% DMSO and read at 550 nM using a Dynatech Microplate Reader MR5000. (Only for Reference)
---------------	--

### Solubility Information

Solubility	DMSO: 132.5 mg/mL (252.59 mM), Sonication is recommended. Ethanol: 39.3 mg/mL (74.92 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.81 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9064 mL	9.5318 mL	19.0636 mL
5 mM	0.3813 mL	1.9064 mL	3.8127 mL
10 mM	0.1906 mL	0.9532 mL	1.9064 mL
50 mM	0.0381 mL	0.1906 mL	0.3813 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Arora S, et al. Cancer Res. 2003, 63(20), 6894-6899.
- Yamamoto K, et al. Biosci Biotechnol Biochem. 2000, 64(4), 919-923.
- Cheng Y, et al. Autophagy. 2013, 9(2), 208-219.
- Usui T, et al. Am J Physiol Heart Circ Physiol. 2013, 305(5), H756-768

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use**

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481